Caring Brands, Inc.

CABR

Nasdaq; chemicals; SIC 2844, Perfumes, Cosmetics & Other Toilet Preparations; CIK 0002020737

None

No letter

3 of 14 inputs computable; 7 are required, with a score in every sleeve

Scoreboard	
Reliability	0.76 AUC filers with under $12.5M assets; 95% interval 0.65 to 0.86; 63 events, 2020 to 2025
Peer failure rate	0.60% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	under $12.5M assets total assets $2.3M
Standard universe	outside revenue above $1M and assets above $10M
Warnings	thin data, degenerate inputs; fortress... not computable: dilution, short runway, distress
Inputs computable	3 of 14
Graded from	filings received through Mar 31, 2026 222 days before the rescan; latest periodic filing 10-Q received Aug 13, 2026
Last close	$1.01 2026-11-06; market equity $10.5M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Mar 31, 2026

are a wellness consumer products company. We offer several over-the-counter (OTC) and cosmetic consumer products. Our product pipeline includes a diverse range of products, such as hair loss treatments, eczema and psoriasis treatments, vitiligo solutions, a jellyfish sting protective suncare line, and women's sexual wellness products, catering to diverse health and wellness needs. Our method of operation ensures that (1) the mechanism of action of all products is established, (2) efficacy is determined through controlled clinical trials, (3) products are protected by issued and filed patents, and (4) products have acceptable commercial stability.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 95.5						
Gross profitability	0.1%	21.4%		95.5	358	2025-12-31
Return on invested capital	not computable	9.3%				
one or more required annual facts are missing						

Accruals ratio	not computable	(4.2%)				
a prior annual assets observation is required						
Gross margin stability, five years	not computable	2.2 pts				
five annual gross margins are required; found 1						
Solvency, sleeve percentile 47.5						
Twelve-month failure probability	not computable	0.04%				
market price is missing at 2025-09-30						
Altman Z double-prime	(11.76)	3.41		91.3	299	2025-12-31
Net debt to EBITDA	not computable	1.88x				
one or more required annual facts are missing						
Interest coverage	not computable	4.16x				
one or more required annual facts are missing						
Current ratio	13.16x	2.20x		3.8	420	2025-12-31
Growth and financing						
Revenue growth, three-year compound	not computable	1.2%				
four annual observations are required; found 1						
Free cash flow growth, three-year compound	not computable	12.5%				
four consecutive annual FCF observations are required; found 0						
Reinvestment rate	not computable	21.8%				
one or more required annual facts are missing						
Asset growth, three years	not computable	2.9%				
four annual observations are required; found 1						
Net share issuance, one year	not computable	0.0%				
two annual share counts are required; found 1						

Warnings

3 of 7 checks triggered; none of them enters the letter

Check	Measured
Thin data	3 of 14 grade factors are computable; minimum is 7
Degenerate inputs	latest revenue or assets are at or below the $100,000 validity floor
Fortress balance sheet	cash minus debt is 2,130,582 USD; Altman Z is not used

What the price implies

at the 2026-11-06 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	not computable	11.0%	
Distance from 52-week high	(36.6%)	(26.1%)	34
EBIT to enterprise value	(67.3%)	3.9%	2
Free cash flow yield	not computable	3.4%	
Book value to price	(0.26)	0.40	2
Sales to price	0.00	0.57	0
Composite equity issuance, five years	not computable	(10.1%)	
Relative strength against the sector, log excess return	not computable	0.00	

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	pass

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	n/a
Operating cash flow, four quarters	n/a
Months of runway	not finite
Days since last periodic filing	87 (10-Q received Aug 13, 2026)
Median daily dollar volume, 63 sessions	$34,318

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	$2,342	2025-12-31	2026-03-31	10-K	26-013844
2	assets	us-gaap:Assets	$2.3M	2025-12-31	2026-03-31	10-K	26-013844
3	net income	us-gaap:NetIncomeLoss	-$6.3M	2025-12-31	2026-03-31	10-K	26-013844
4	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$1.7M	2025-12-31	2026-03-31	10-K	26-013844
5	current assets	us-gaap:AssetsCurrent	$2.3M	2025-12-31	2026-03-31	10-K	26-013844
6	current liabilities	us-gaap:LiabilitiesCurrent	$176,844	2025-12-31	2026-03-31	10-K	26-013844
7	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$7.1M	2025-12-31	2026-03-31	10-K	26-013844
8	operating income	us-gaap:OperatingIncomeLoss	-$5.9M	2025-12-31	2026-03-31	10-K	26-013844
9	book equity	us-gaap:StockholdersEquity	$2.1M	2025-12-31	2026-03-31	10-K	26-013844
10	liabilities	us-gaap:Liabilities	$235,494	2025-12-31	2026-03-31	10-K	26-013844
11	revenue	us-gaap:Revenues	$4,215	2025-12-31	2026-03-31	10-K	26-013844
12	shares outstanding	dei:EntityCommonStockSharesOutstanding	12,341,506	2026-03-30	2026-03-31	10-K	26-013844

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.